Sclerotherapy for intractable ganglion cyst of the hallux

Yasuhito Tanaka, Yoshinori Takakura, Tsukasa Kumai, Kazuya Sugimoto, Akira Taniguchi, Koji Hattori

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: We devised a method of sclerotherapy using OK432. The present study comprised a retrospective followup of sclerotherapy outcomes. Materials and Methods: Eighteen feet in 18 consecutive patients (seven men, 11 women; mean age, 55 years) were treated with sclerotherapy. Previous surgery had been performed one to four times for seven feet. After aspirating the contents of the ganglion cysts, 0.2 to 0.3 ml of suspension of OK432 (lyophilized strep pyogenes) was injected. The volume of fluid aspirated was from 0.2 to 2.5 ml, with an average of 0.9 ml. Mean duration of followup was 3 years 6 months. Clinical evaluation was performed using the AOFAS hallux scale. Results: All ganglion cysts disappeared after sclerotherapy. However, recurrences were observed in eight feet. Mean duration until recurrence was 13 months. Sclerotherapy was again performed for all patients with recurrence. Re-recurrence occurred in three feet. A third sclerotherapy was performed for all three patients. All ganglion cysts had disappeared by final followup. Mean AOFAS score improved from 75 points before therapy to 95 points at followup. Six patients had complications with local redness and pain for 1 to 6 days after injection. Conclusion: Sclerotherapy using OK432 is a minimally invasive treatment of symptomatic ganglion cysts of the hallux. Recurrence is common but complications are infrequent and self-limited.

Original languageEnglish
Pages (from-to)128-132
Number of pages5
JournalFoot and Ankle International
Volume30
Issue number2
DOIs
Publication statusPublished - 2009 Feb
Externally publishedYes

Fingerprint

Ganglion Cysts
Hallux
Sclerotherapy
Recurrence
Suspensions
Pain
Injections
Therapeutics

Keywords

  • Ganglion
  • Hallux
  • OK432
  • Sclerotherapy

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Tanaka, Y., Takakura, Y., Kumai, T., Sugimoto, K., Taniguchi, A., & Hattori, K. (2009). Sclerotherapy for intractable ganglion cyst of the hallux. Foot and Ankle International, 30(2), 128-132. https://doi.org/10.3113/FAI.2009.0128

Sclerotherapy for intractable ganglion cyst of the hallux. / Tanaka, Yasuhito; Takakura, Yoshinori; Kumai, Tsukasa; Sugimoto, Kazuya; Taniguchi, Akira; Hattori, Koji.

In: Foot and Ankle International, Vol. 30, No. 2, 02.2009, p. 128-132.

Research output: Contribution to journalArticle

Tanaka, Y, Takakura, Y, Kumai, T, Sugimoto, K, Taniguchi, A & Hattori, K 2009, 'Sclerotherapy for intractable ganglion cyst of the hallux', Foot and Ankle International, vol. 30, no. 2, pp. 128-132. https://doi.org/10.3113/FAI.2009.0128
Tanaka, Yasuhito ; Takakura, Yoshinori ; Kumai, Tsukasa ; Sugimoto, Kazuya ; Taniguchi, Akira ; Hattori, Koji. / Sclerotherapy for intractable ganglion cyst of the hallux. In: Foot and Ankle International. 2009 ; Vol. 30, No. 2. pp. 128-132.
@article{236c16dd8e1f4cd78296f785a9a4b390,
title = "Sclerotherapy for intractable ganglion cyst of the hallux",
abstract = "Background: We devised a method of sclerotherapy using OK432. The present study comprised a retrospective followup of sclerotherapy outcomes. Materials and Methods: Eighteen feet in 18 consecutive patients (seven men, 11 women; mean age, 55 years) were treated with sclerotherapy. Previous surgery had been performed one to four times for seven feet. After aspirating the contents of the ganglion cysts, 0.2 to 0.3 ml of suspension of OK432 (lyophilized strep pyogenes) was injected. The volume of fluid aspirated was from 0.2 to 2.5 ml, with an average of 0.9 ml. Mean duration of followup was 3 years 6 months. Clinical evaluation was performed using the AOFAS hallux scale. Results: All ganglion cysts disappeared after sclerotherapy. However, recurrences were observed in eight feet. Mean duration until recurrence was 13 months. Sclerotherapy was again performed for all patients with recurrence. Re-recurrence occurred in three feet. A third sclerotherapy was performed for all three patients. All ganglion cysts had disappeared by final followup. Mean AOFAS score improved from 75 points before therapy to 95 points at followup. Six patients had complications with local redness and pain for 1 to 6 days after injection. Conclusion: Sclerotherapy using OK432 is a minimally invasive treatment of symptomatic ganglion cysts of the hallux. Recurrence is common but complications are infrequent and self-limited.",
keywords = "Ganglion, Hallux, OK432, Sclerotherapy",
author = "Yasuhito Tanaka and Yoshinori Takakura and Tsukasa Kumai and Kazuya Sugimoto and Akira Taniguchi and Koji Hattori",
year = "2009",
month = "2",
doi = "10.3113/FAI.2009.0128",
language = "English",
volume = "30",
pages = "128--132",
journal = "Foot and Ankle International",
issn = "1071-1007",
publisher = "AOFAS - American Orthopaedic Foot and Ankle Society",
number = "2",

}

TY - JOUR

T1 - Sclerotherapy for intractable ganglion cyst of the hallux

AU - Tanaka, Yasuhito

AU - Takakura, Yoshinori

AU - Kumai, Tsukasa

AU - Sugimoto, Kazuya

AU - Taniguchi, Akira

AU - Hattori, Koji

PY - 2009/2

Y1 - 2009/2

N2 - Background: We devised a method of sclerotherapy using OK432. The present study comprised a retrospective followup of sclerotherapy outcomes. Materials and Methods: Eighteen feet in 18 consecutive patients (seven men, 11 women; mean age, 55 years) were treated with sclerotherapy. Previous surgery had been performed one to four times for seven feet. After aspirating the contents of the ganglion cysts, 0.2 to 0.3 ml of suspension of OK432 (lyophilized strep pyogenes) was injected. The volume of fluid aspirated was from 0.2 to 2.5 ml, with an average of 0.9 ml. Mean duration of followup was 3 years 6 months. Clinical evaluation was performed using the AOFAS hallux scale. Results: All ganglion cysts disappeared after sclerotherapy. However, recurrences were observed in eight feet. Mean duration until recurrence was 13 months. Sclerotherapy was again performed for all patients with recurrence. Re-recurrence occurred in three feet. A third sclerotherapy was performed for all three patients. All ganglion cysts had disappeared by final followup. Mean AOFAS score improved from 75 points before therapy to 95 points at followup. Six patients had complications with local redness and pain for 1 to 6 days after injection. Conclusion: Sclerotherapy using OK432 is a minimally invasive treatment of symptomatic ganglion cysts of the hallux. Recurrence is common but complications are infrequent and self-limited.

AB - Background: We devised a method of sclerotherapy using OK432. The present study comprised a retrospective followup of sclerotherapy outcomes. Materials and Methods: Eighteen feet in 18 consecutive patients (seven men, 11 women; mean age, 55 years) were treated with sclerotherapy. Previous surgery had been performed one to four times for seven feet. After aspirating the contents of the ganglion cysts, 0.2 to 0.3 ml of suspension of OK432 (lyophilized strep pyogenes) was injected. The volume of fluid aspirated was from 0.2 to 2.5 ml, with an average of 0.9 ml. Mean duration of followup was 3 years 6 months. Clinical evaluation was performed using the AOFAS hallux scale. Results: All ganglion cysts disappeared after sclerotherapy. However, recurrences were observed in eight feet. Mean duration until recurrence was 13 months. Sclerotherapy was again performed for all patients with recurrence. Re-recurrence occurred in three feet. A third sclerotherapy was performed for all three patients. All ganglion cysts had disappeared by final followup. Mean AOFAS score improved from 75 points before therapy to 95 points at followup. Six patients had complications with local redness and pain for 1 to 6 days after injection. Conclusion: Sclerotherapy using OK432 is a minimally invasive treatment of symptomatic ganglion cysts of the hallux. Recurrence is common but complications are infrequent and self-limited.

KW - Ganglion

KW - Hallux

KW - OK432

KW - Sclerotherapy

UR - http://www.scopus.com/inward/record.url?scp=60849084151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60849084151&partnerID=8YFLogxK

U2 - 10.3113/FAI.2009.0128

DO - 10.3113/FAI.2009.0128

M3 - Article

C2 - 19254507

AN - SCOPUS:60849084151

VL - 30

SP - 128

EP - 132

JO - Foot and Ankle International

JF - Foot and Ankle International

SN - 1071-1007

IS - 2

ER -